

Review on Mucormycosis

Anushri Shirirao¹, Rajlaxmi Deolekar², Rakesh Bagul³

New Montfort Institute of Pharmacy, Ashti, Wardha, Maharashtra, India
anushrishirirao@gmail.com

Abstract: *An increasing number of virulent, angioinvasive spores belonging to the order Mucorales are known to infect individuals who are immunocompromised with potentially fatal diseases. The prognosis for this debilitating infection has improved because of advances in pathophysiology understanding, early detection, and the recent development of active, nontoxic medications. However, due in part to the limited yield and complexity of culture-based and molecular diagnostic approaches, rates of delayed diagnosis and mortality remain high. Novel diagnostic techniques and efficient treatment modalities are thus desperately needed.*

Keywords: Amphotericin, Isavuconazole, Ketoacidosis, Diabetes, Hematopoietic stem cell transplantation, Immuno compromised

REFERENCES

- [1]. Introduction to Mycology <https://www.ncbi.nlm.nih.gov/books/NBK8125/> McGinnis MR, Tying SK.
- [2]. Fungi By: BD Editors Reviewed by: BD Editors <https://biologydictionary.net/fungi/>
- [3]. Fungus Wikipedia <https://en.m.wikipedia.org/wiki/Fungus>
- [4]. Physical Chemical Properties of Fungi M. McConnaughey, in Reference Module in Biomedical Sciences, 2014
- [5]. Recent Advances in the Treatment of Mucormycosis Brad Spellberg and Ashraf S. Ibrahim <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947016/>
- [6]. Farmakiotis D, Kontoyiannis DP. Mucormycoses. *Infect Dis Clin North Am.* 2016;30:143- 163. <https://www.ncbi.nlm.nih.gov/pubmed/26897065>
- [7]. Danion F, Aguilar C, Catherinot E, et al. Mucormycosis: new developments into a persistently devastating infection. *Semin Respir Crit Care Med.* 2015;36:692-705. <https://www.ncbi.nlm.nih.gov/pubmed/26398536>
- [8]. Kontoyiannis DP, Azie N, Franks B, Horn DL. Prospective antifungal therapy (PATH) alliance®: focus on mucormycosis. *Mycoses.* 2014;57:240-246. <https://www.ncbi.nlm.nih.gov/pubmed/24147728>
- [9]. Binder U, Mauer E, Lass-Flörl C. Mucormycosis – from the pathogens to the disease. *Clin Microbiol Infect.* 2014;20:60-66. <https://www.ncbi.nlm.nih.gov/pubmed/24476149>
- [10]. Lelievre L, Garcia-Hermoso D, Abdoul H, et al. Posttraumatic mucormycosis. *Medicine (Baltimore).* 2014;93:395-404. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602436/>
- [11]. Fungi By: BD Editors Reviewed by: BD Editors <https://biologydictionary.net/fungi/>
- [12]. Recent Advances in the Treatment of Mucormycosis Brad Spellberg and Ashraf S. Ibrahim <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947016/>
- [13]. Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficult to cure than more common mycoses? *Clin Microbiol Infect.* 2014;20:74-81. <https://www.ncbi.nlm.nih.gov/pubmed/24279587>
- [14]. Binder U, Mauer E, Lass-Flörl C. Mucormycosis – from the pathogens to the disease. *Clin Microbiol Infect.* 2014;20:60-66. <https://www.ncbi.nlm.nih.gov/pubmed/24476149>

- [15]. Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). *Haematologica*. 2013;98:492-504.
<https://www.ncbi.nlm.nih.gov/pubmed/22983580>
- [16]. Recent Advances in the Treatment of Mucormycosis Brad Spellberg and Ashraf S. Ibrahim
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947016/>
- [17]. Kontoyiannis DP, Lewis RE, Latholary O, et al. Future directions in mucormycosis research. *Clin Infect Dis*. 2012;54:S79-S85.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258101/>
- [18]. Fungi By: BD Editors Reviewed by: BD Editors <https://biologydictionary.net/fungi/>
- [19]. Kontoyiannis DP, Lewis RE, Latholary O, et al. Future directions in mucormycosis research. *Clin Infect Dis*. 2012;54:S79-S85.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258101/>
- [20]. Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). *Haematologica*. 2013;98:492-504.
<https://www.ncbi.nlm.nih.gov/pubmed/22983580>
- [21]. Lelievre L, Garcia-Hermoso D, Abdoul H, et al. Posttraumatic mucormycosis. *Medicine (Baltimore)*. 2014;93:395-404.
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602436/>
- [22]. Katragkou A, Walsh TJ, Roilides E. Why is mucormycosis more difficult to cure than more common mycoses? *Clin Microbiol Infect*. 2014;20:74-81.
<https://www.ncbi.nlm.nih.gov/pubmed/24279587>
- [23]. Danion F, Aguilar C, Catherinot E, et al. Mucormycosis: new developments into a persistently devastating infection. *Semin Respir Crit Care Med*. 2015;36:692-705.
<https://www.ncbi.nlm.nih.gov/pubmed/26398536>
- [24]. Introduction to Mycology <https://www.ncbi.nlm.nih.gov/books/NBK8125/> McGinnis MR, Tying SK.